BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, July 13, 2026
Home » Topics » Financings

Financings
Financings RSS Feed RSS

Apimeds prices $11.5M IPO for bee venom-based therapy

Sep. 30, 2024
By Marian (YoonJee) Chu
Apimeds Pharmaceuticals US Inc., a subsidiary of Seoul, South Korea-based Inscobee Inc., is “counting down” to an official IPO on the New York Stock Exchange with its S-1 filing showing a targeted offering of $11.5 million.
Read More

Financings for Sept. 30, 2024

Sep. 30, 2024
Biopharmas raising money in public or private financings, including: Cue, Eyenovia, Nurexone, Theriva.
Read More

Financings for September 30, 2024

Sep. 30, 2024
Med-tech firms raising money in public or private financings, including: Brainsway, Mindpeak, Perimeter Medical Imaging.
Read More
3D Euro symbol

Asabys’ €180M fund to support Europe’s life sciences ecosystem

Sep. 30, 2024
By Nuala Moran
Spanish VC firm Asabys Partners has closed its second fund at €180 million (US$201.3 million), to be invested in seed to series B rounds in 12 to 15 biotech, med-tech and digital health companies.
Read More
Globe and currency symbols

Asabys Partners closes $200M fund

Sep. 27, 2024
By Shani Alexander
Venture Capital firm Asabys Partners closed its second fund, Sabadell Asabys Health Innovation Investments II, with total commitments of €180 million ($200 million). The funds will go towards 12 to 15 companies developing health care solutions across the medical device, digital health and biopharma fields.
Read More
3D Euro symbol

Asabys’ €180M fund to support Europe’s life sciences ecosystem

Sep. 27, 2024
By Nuala Moran
Spanish VC firm Asabys Partners has closed its second fund at €180 million (US$201.3 million), to be invested in seed to series B rounds in 12 to 15 biotech, med-tech and digital health companies.
Read More

Financings for Sept. 27, 2024

Sep. 27, 2024
Biopharmas raising money in public or private financings, including: 858 Therapeutics, Apimeds, Inscobee, Mirai, Wave Life Sciences.
Read More

Financings for September 27, 2024

Sep. 27, 2024
Med-tech firms raising money in public or private financings, including: Eyenovia, Venus Concept.
Read More

Financings for Sept. 26, 2024

Sep. 26, 2024
Biopharmas raising money in public or private financings, including: Alpha Cognition, Bioage Labs.
Read More

Financings for September 26, 2024

Sep. 26, 2024
Med-tech firms raising money in public or private financings, including: Mdxhealth, Mendaera, Qure.ai.
Read More
Previous 1 2 … 164 165 166 167 168 169 170 171 172 … 682 683 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 10, 2026.
  • Silhouette with keyhole

    FENS 2026: Next-gen biologics take on brain disease

    BioWorld
    Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
  • Wainua autoinjector

    Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy

    BioWorld
    News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
  • Art concept for medical research

    FENS 2026: Shedding light on the sheddome

    BioWorld
    At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
  • NRF2 activators reported in Vailima Peninsula patent

    BioWorld Science
    Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing